Eslicarbazepine Acetate Monotherapy Long Term Study

NCT ID: NCT00910247

Last Updated: 2018-07-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

274 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-31

Study Completion Date

2017-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a long term, open-label, safety extension study in subjects with partial onset seizures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a long term, multicenter, open-label, safety extension study in subjects with partial onset seizures who have just completed, discontinued, or exited the 18-week treatment phase of Protocols 093-045 or 093-046. The initial study duration is 1 year with the option of continuing study drug treatment post 1 year until a subject discontinues study, the study drug becomes clinically available in the subject's locale, or the sponsor terminates the study drug clinical development program.

This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

eslicarbazepine acetate

Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD

Group Type EXPERIMENTAL

Eslicarbazepine acetate

Intervention Type DRUG

800 to 2400 mg once daily (QD)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eslicarbazepine acetate

800 to 2400 mg once daily (QD)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SEP-0002093 BIA 2-093

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Subject who completed, exited, or discontinued for reasons other than safety from the 18-week treatment phase of Protocols 093-045 or 093-046 and are willing to continue participation in this study are eligible. Subject must have completed at least the first 3 weeks of the 18-week double-blind treatment period of Protocols 093-045 or 093-046 to be eligible.
* Subject must give written informed consent prior to participation in the study. For subjects \<18 years of age, the informed consent must be signed by the subject's parent or legal guardian, and, when appropriate and/or required by state or local law, minor subjects must give written informed assent prior to participation in the study. All subjects must sign privacy authorization form, if applicable. All females of child bearing potential (≤65 years of age) must also sign the "Women of Childbearing Potential" Addendum.
* Subjects must, in the opinion of the Investigator (with consultation with Medical Monitor as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation.
* If female subject, must continue the accepted method of birth control defined in Protocols 093-045 or 093-046 for the duration of this study as well
* Criterion for Continuation into the Post 1 year Part of Study:

For subjects to continue into the post 1 year part of the study, subjects must, in the opinion of the Investigator (with consultation with Medical Monitor, as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation.
Minimum Eligible Age

16 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sumitomo Pharma America, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

CNS Medical Director

Role: STUDY_DIRECTOR

Sunovion Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neurology Clinic, P.C.

Northport, Alabama, United States

Site Status

21st Century Neurology, a division of Xenoscience, Inc.

Phoenix, Arizona, United States

Site Status

Clinical Research Consortium-Arizona

Phoenix, Arizona, United States

Site Status

Arizona Neurological Institute

Sun City, Arizona, United States

Site Status

Center for Neurosciences

Tucson, Arizona, United States

Site Status

University of Arizona, Health Sciences Center

Tucson, Arizona, United States

Site Status

Arkansas Neurology

Conway, Arkansas, United States

Site Status

K&S Professional Research Services, LLC

Little Rock, Arkansas, United States

Site Status

Sutter East Bay Medical Foundation

Berkeley, California, United States

Site Status

Neuro-Pain Medical Center

Fresno, California, United States

Site Status

Collaborative Neuroscience Network

Garden Grove, California, United States

Site Status

Faculty of Physicians and Surgeons of Loma Linda University

Loma Linda, California, United States

Site Status

Viking Clinical Research Center

Murrieta, California, United States

Site Status

Viking Clinical Research

Murrieta, California, United States

Site Status

Northridge Neurological Research Center

Northridge, California, United States

Site Status

Yafa Minazad

Pasadena, California, United States

Site Status

Neurological Research Institute

Santa Monica, California, United States

Site Status

Collaborative Neuroscience Network

Torrance, California, United States

Site Status

Neurosearch II Inc

Ventura, California, United States

Site Status

Neurosciences Clinic - University of Colorado Hospital

Aurora, Colorado, United States

Site Status

Denver Health

Denver, Colorado, United States

Site Status

Associated Nuerologists, PC

Danbury, Connecticut, United States

Site Status

JEM Research, LLC

Atlantis, Florida, United States

Site Status

Bradenton Clinical Research

Bradenton, Florida, United States

Site Status

Miami Research Inc.

Coral Gables, Florida, United States

Site Status

NW FL Clinical Research Group, LLC

Gulf Breeze, Florida, United States

Site Status

Palm Springs Research Institute

Hialeah, Florida, United States

Site Status

Infinity Clinical Research, LLC

Hollywood, Florida, United States

Site Status

Neurology Associates

Maitland, Florida, United States

Site Status

San Marcus Research Clinic

Miami, Florida, United States

Site Status

Miami Children's Hospital

Miami, Florida, United States

Site Status

Neuroscience Consultants

Miami, Florida, United States

Site Status

Pediatric Neurology, PA

Orlando, Florida, United States

Site Status

Neurology Associates of Ormond Beach

Ormond Beach, Florida, United States

Site Status

Bay Neurological Institute

Panama City, Florida, United States

Site Status

Medsol Clinical Research Center

Port Charlotte, Florida, United States

Site Status

Pediatric Epilepsy & Neurology Specialists, PA

Tampa, Florida, United States

Site Status

Palm Beach Clinical Research Network, LLC

Wellington, Florida, United States

Site Status

PANDA Neurology and Atlanta Heachache Specialists

Atlanta, Georgia, United States

Site Status

Harbin Clinic

Rome, Georgia, United States

Site Status

Consultants in Epilepsy and Nuerology

Boise, Idaho, United States

Site Status

OSF Saint Francis Medical Center

Peoria, Illinois, United States

Site Status

Southern Illinois University School of Medicine

Springfield, Illinois, United States

Site Status

Central DuPage Hospital

Winfield, Illinois, United States

Site Status

J.W.M. Neurology P.C.

Indianapolis, Indiana, United States

Site Status

McFarland Clinic, PC

Ames, Iowa, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Bluegrass Epilepsy Research, LLC

Lexington, Kentucky, United States

Site Status

ECommunity Research LLC

Hammond, Louisiana, United States

Site Status

MMP Neuroloy

Scarborough, Maine, United States

Site Status

Johns Hopkins University

Baltimore, Maryland, United States

Site Status

Mid-Atlantic Epilepsy and Sleep Center

Bethesda, Maryland, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Lahey Clinic

Burlington, Massachusetts, United States

Site Status

Wayne State University/Detroit Medical Center

Detroit, Michigan, United States

Site Status

Minneappolis Clinic of Neurology

Golden Valley, Minnesota, United States

Site Status

Precise Research Centers

Flowood, Mississippi, United States

Site Status

Comprehensive Epilepsy Care Center for Children and Adults

Chesterfield, Missouri, United States

Site Status

PsychCare Consultants Research

St Louis, Missouri, United States

Site Status

Northeast Regional Epilepsy Group

Hackensack, New Jersey, United States

Site Status

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

Site Status

University Medicine and Dentistry of New Jersey

New Brunswick, New Jersey, United States

Site Status

UMDNJ DOC 8th Floor 8100

Newark, New Jersey, United States

Site Status

Five Towns Neuroscience Research

Cedarhurst, New York, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

SUNY Upstate Medical University

Syracuse, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

PMG Research of Hickory, LLC

Hickory, North Carolina, United States

Site Status

Department of Neurology

Winston-Salem, North Carolina, United States

Site Status

Ohio Clinical Research Partners, LLC

Canton, Ohio, United States

Site Status

The University of Toledo Health Science Campus

Toledo, Ohio, United States

Site Status

Lynn Health Science Institute

Oklahoma City, Oklahoma, United States

Site Status

Sooner Clinical Research

Oklahoma City, Oklahoma, United States

Site Status

Tulsa Clinical Research LLC

Tulsa, Oklahoma, United States

Site Status

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Site Status

Temple University School of Medicine, Dept of Neurology

Philadelphia, Pennsylvania, United States

Site Status

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States

Site Status

Gus Stratton / Neurology

Cranston, Rhode Island, United States

Site Status

VU Department of Neurology

Nashville, Tennessee, United States

Site Status

Neurology Associates of Arlington, P.A.

Arlington, Texas, United States

Site Status

Edwin A Green, Jr., MD

Brownwood, Texas, United States

Site Status

Texas Neurology, PA

Dallas, Texas, United States

Site Status

Neurological Clinic of Texas, P.A.

Dallas, Texas, United States

Site Status

UT Health Science Center at Houston/ Dept of Neurology

Houston, Texas, United States

Site Status

MD

Houston, Texas, United States

Site Status

Neurology Associates of Arlington, P.A.

Mansfield, Texas, United States

Site Status

Innovative Clinical Trials

San Antonio, Texas, United States

Site Status

Road Runner Research

San Antonio, Texas, United States

Site Status

Scott and White Memorial Hospital

Temple, Texas, United States

Site Status

University of Utah Department of Neurology

Salt Lake City, Utah, United States

Site Status

Neurological Associates of Washington

Bellevue, Washington, United States

Site Status

Rainier Clinical Research Center Inc.

Renton, Washington, United States

Site Status

Pacific Medical Centers

Seattle, Washington, United States

Site Status

West Virginia University

Morgantown, West Virginia, United States

Site Status

Regional Epilepsy Center

Milwaukee, Wisconsin, United States

Site Status

Multiprofile Hospital for Active Treatment "Pulse," AD, Town of Blagoegrad

Blagoevgrad, , Bulgaria

Site Status

Univesity Multiprofile Hospital for Active Treatment "Dr. George Stranski," EAD, town of Pleven

Pleven, , Bulgaria

Site Status

Second Multiprofile Hospital for Active Treatment

Sofia, , Bulgaria

Site Status

Diagnostic and Consultative Center "Equita" EOOD, town of Varna Neurology office

Varna, , Bulgaria

Site Status

London Health Sciences Centre, University Campus

London, Ontario, Canada

Site Status

Neuro-Epilepsy Clinic/ Neuro Rive-Sud

Greenfield Park, Quebec, Canada

Site Status

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

Site Status

Policlinic Chocen, Private Neurology

Smetanova Lhota, Chocen, Czechia

Site Status

Cerebrovaskularni poradna s.r.o

Třebovice, Ostrava, Czechia

Site Status

CTC Rychnov nad Kneznou

Rychnov nad Kněžnou, Praugue, Czechia

Site Status

Evzen Nespor

Prague, Strasnice, Czechia

Site Status

Poradna pro epilepsie

Koty, Zlín, Czechia

Site Status

Neurologicka ordinance

Prague, , Czechia

Site Status

Clinic of Neurology, Clinical Center of Serbia

Belgrade, , Serbia

Site Status

Institute of Mental Health, Department of epilepsy and clinical neurophysiology

Belgrade, , Serbia

Site Status

Communal Institution "Dnipropetrovsk Regional Clinical Hospital named after l.l. Mechnikov" Regional Center of psychosomatic disorders, Psychoneurology department for patients with psychosomatic disorders and borderline conditions

Dnipropetrovsk, , Ukraine

Site Status

Communal Medical and Preventive Treatment Institution "Regional Clinical Psychiatric Hospital" Donetsk National Medical University

Donetsk, , Ukraine

Site Status

State Treatment and Prevention Institution " Central clinical hospital of Ukrzalizntysya" Neurology Department of Neuropathology and Child Neurology

Kharkiv, , Ukraine

Site Status

State Institution "Institute of neurology, psychiatry, and narcology of AMS of Ukraine" Department of cerebrovascular patology

Kharkiv, , Ukraine

Site Status

State Institution "Institute of the Health Care of Children and Adolescents of Academy of Medical Sciences of Ukraine Dept of Psych

Kharkiv, , Ukraine

Site Status

State Institution Railway Clinical Hospital #1 of Kiev Railway Station of DTGO South Western Railroad Psycho-neurological Department

Kiev, , Ukraine

Site Status

Communal Institution "Lviv Regional Clinical Psych Hospital"

Lviv, , Ukraine

Site Status

Communal Institution "Odessa Regional Clinical Psych Hospital #1" Department of Day Care

Odesa, , Ukraine

Site Status

Poltava Regional Clinical Psychiatric Hospital named O.F. Maltsev

Poltava, , Ukraine

Site Status

Crimean Republican Institution "Clinical Psychiatric Hospital #1"

Simferopol, , Ukraine

Site Status

Communal Institution "Vinnystsia Regional Psycho-Neurological Hospital named after O.I. Yuschenko, Vinnytsia National Medical University named after M.I. Pirogov, Dispensary department, Department of Psychiatry and Addictology

Vinnytsia, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Canada Czechia Serbia Ukraine

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol: Final

View Document

Document Type: Study Protocol: Amendment history

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

093-050

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.